Evon, Donna M. http://orcid.org/0000-0002-1414-1846
Kim, Hannah P.
Edwards, Angela
Carda-Auten, Jessica
Reeve, Bryce B.
Golin, Carol E.
Fried, Michael W.
Funding for this research was provided by:
National Institutes of Health (DK056350, P30 AI050410, T32 DK007634)
National Cancer Institute (P30-CA16086)
National Center for Advancing Translational Sciences (UL1TR002489)
Article History
Received: 8 April 2020
Accepted: 7 January 2021
First Online: 2 February 2021
Compliance with Ethical Standards
:
: Donna M. Evon has received research funding from Gilead Sciences, Inc. and Merck Sharp and Dohme. Michael W. Fried has received research funding from and served as a consultant for AbbVie, BMS, Gilead, Merck, and TARGET PharmaSolutions. Stock in TARGET PharmaSolutions is held in an independently managed trust. Angela Edwards, Jessica Carda-Auten, Bryce B. Reeve, Carol E. Golin, and Hannah P. Kim declare that they have no conflict of interest.